Cantargia publishes interim report for January – September 2016
Cantargia AB (“Cantargia”) interim report for January – September 2016 is available on the company website (www.cantargia.com/Investors/Reports).Significant events in the third quarter The US patent office granted two of Cantargias patent applications; i.e. the application for the use of IL1RAP as target molecule for antibody-based treatment of solid tumors and as well as the application for IL1RAP as a target for antibody-based treatment of acute lymphoblastic leukemia (ALL). Cantargia raised SEK 250,212.50 through the exercise of warrants of series 2011/2016 by Agneta Svedberg, the